Dot Compliance, a supplier of AI-enabled quality management system (QMS) solutions secures $17.5million in series B round funding. Leading the round, which increased the total to $50 million, were IGP Capital and Vertex Ventures, with TPY Capital also participating.
The firm plans to utilise the money to satisfy the growing market need for AI-driven solutions that enable health sciences organisations better quality control and dynamic compliance requirements, as well as to accelerate the development of its AI software solutions, continue product innovation, and expand its client base.
Read also – NYC-based Monad Labs Secures $225Million in Series A Round Funding
Dot Compliance provides an intuitive quality management solution driven by the Salesforce.com platform, under the direction of its founder and CEO, Doron Sitbon. Customers may install it swiftly and affordably thanks to its suite of pre-configured compliance practice processes and a wide range of readily available off-the-shelf QMS.
With over 400,000 customers, the solutions are utilised by health sciences organisations of all sizes across the globe and are fully compliant with EU-Annex 11 and 21 CFR part 11. They also support ISO 9001, 13485, 14971, and 27001 standards.
Doron Sitbon said: “This funding will allow us to accelerate our momentum and double down on our AI solution. We are thrilled to be able to offer a solution that makes AI-powered insights accessible to all in the life sciences industry, regardless of what data sources they currently use. Dot Compliance is transforming into a data company as we create a new category of AI-driven compliance.”
About Dot Compliance
The first fully functional eQMS for life sciences driven by AI is called Dot Compliance. Biotechnology, pharmaceutical, and medical device industries may get products to market more quickly and affordably using Dot Compliance’s eQMS, which is packed with generative AI capabilities.
